- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2023–2027 · grant · BCRP
Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer
Judith Agudo · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2028 · career development · K08
Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment
Riaz Gillani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · career development · K99
Targeting Menin Protein Stability In AML
Jevon Cutler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · grant · PRCRP
Dissecting the Role of DNA Damage Repair Deficiency in Ewing Sarcoma Pathogenesis Through Integrative Computational Biology
Riaz Gillani · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2028 · program · P50
DF/HCC Prostate SPORE
Steven P. Balk · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · grant · KCRP
The Effect of Clonal Hematopoiesis on Cardiovascular-Related Outcomes in Patients Diagnosed with Kidney Cancer
Maxine Sun · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2026 · award
Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment
Riaz Gillani · Dana-Farber Cancer Institute · funded by American Cancer Society
2023–2025 · fellowship · F32
Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability.
Michelle Swift · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · grant · PRCRP
Measurement and Impact of Body Composition Using CT Imaging in Patients with Germ Cell Tumors Undergoing Chemotherapy on the NCTN Phase 3 Study AGCT1531
Christina Dieli-Conwright · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2027 · research · R01
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies
Constantine S. Mitsiades · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · cooperative agreement · U54
The Center for Synovial Sarcoma Biology and Therapeutics
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023 · grant · Bourses postdoctorales (citoyens canadiens et résidents permanents) — Formation postdoctorale - Citoyens canadiens et résidents permanents
Bourses postdoctorales (citoyens canadiens et résidents permanents) — Cancer du sang, Hématologie
Meaghan Boileau · Dana-Farber Cancer Institute · funded by Fonds de Recherche du Québec - Santé
2023–2028 · career development · K08
Harnessing the repetitive genome for cancer immunotherapy
Gabriel K. Griffin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · award
Determining the contribution of transposable elements to ovarian cancer establishment and progression
Jennifer Karlow · Dana-Farber Cancer Institute · funded by American Cancer Society
2023 · research · Research
Patient-Level Artificial Intelligence To Derive Longitudinal Phenotypes for CER
Kenneth Kehl · Dana-Farber Cancer Institute · funded by Patient-Centered Outcomes Research Institute
2023–2024 · cooperative agreement · U2C
The Cellular Geography of Therapeutic Resistance in Cancer
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · research · R56
Integrative modelling of single-cell data to elucidate the genetic architecture of complex disease
Alexander Gusev · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · career development · K99
Mechanisms of mitochondrial-ER communication during dietary and thermal induced stress
Pedro Antonio Latorre Muro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · career development · K08
Harnessing the repetitive genome for cancer immunotherapy
Gabriel K. Griffin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · program · P30
Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer
Laurie Hollis Glimcher · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · grant · Continuing Grant
CAREER: Synthesis and Application of Bioorthogonally Degradable Polymers
Justin Kim · Dana-Farber Cancer Institute · funded by National Science Foundation
2023–2024 · grant · RCRP
Dissecting the Difference in the Pathogenesis and Immune Microenvironment of Pediatric and Adult Osteosarcoma
Erica Pimenta · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2028 · cooperative agreement · U01
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma
Robbie G. Majzner · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · grant · LCRP
Interpretable Machine Learning for Molecular Discovery in Lung Cancer
Haitham Elmarakeby · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2025 · research · R37
Acupuncture for Chemothrapy-induced Peripheral Neuropathy Treatment (ACT) Trial
Ting Bao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Probing the role of somatic X-chromosome alterations in shaping cancer sex differences
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · research · R21
Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2030 · research · R35
Targeting Pediatric Cancer Vulnerabilities
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
Miguel Nicolas Rivera · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · program · P30
Real-World Molecularly Targeted Treatment Registry (MaTTeR): a Pilot Study to Enrich CCDI Data Utilizing Directed Electronic Medical Record (EMR) Extraction
Laurie Hollis Glimcher · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
Mohammad Rashidian · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
Miguel Nicolas Rivera · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies
Constantine S. Mitsiades · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · career development · K08
Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment
Riaz Gillani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer
Andrew James Aguirre · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · grant · KCRP
Tumor-Intrinsic and Tumor-Extrinsic Determinants of Immune Responsiveness in MiT/TFE Translocation Renal Cell Carcinoma
Prathyusha Konda · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2026 · grant · OT2
NexTGen - DFCI
Robbie G. Majzner · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · career development · K99
Mechanisms of mitochondrial-ER communication during dietary and thermal induced stress
Pedro Antonio Latorre Muro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · career development · K00
Fertility legislation and unmet needs: Exploring intervenable barriers for quality oncofertility care among adolescent and young adult cancer patients
Julia Stal · Dana-Farber Cancer Institute · funded by National Institutes of Health
